Dexmedetomidine vs. Remifentanil Undergoing Cataract Surgery in Geriatrics
Geriatrics, Outpatients, Personal Satisfaction
About this trial
This is an interventional supportive care trial for Geriatrics focused on measuring geriatrics, ambulatory surgery, cataract, anesthesia, conscious sedation, dexmedetomidine, remifentanil
Eligibility Criteria
Inclusion Criteria:
- Patients between the ages of 65-80,
- Who will undergo cataract surgery,
- With the American Society of Anesthesiologists (ASA) score I-III.
Exclusion Criteria:
- Second or third-degree heart block,
- Chronic α2-agonist use,
- Inability to communicate with the patient,
- Uncontrolled systemic disease,
- Allergy to local anesthetics,
- Chronic analgesic or sedative drug use,
- History of alcohol or substance addiction.
Sites / Locations
- Hacettepe University
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Dexmedetomidine infusion
Remifentanil infusion
Dexmedetomidine (Precedex, Meditera, USA) was administered at a loading dose of 1 µg/kg for 10 minutes before local anesthesia to be applied to the eye by the surgeon. During the surgical procedure, it was administered at a dose of 0.4 µg/kg/h-1 infusion.
Remifentanil (Ultiva, Glaxo SmithKline, Turkey) infusion was started at a dose of 0.05 µg/kg/min-1, 10 minutes before the start of the surgery as baseline infusion and continued at the same infusion dose throughout the surgical procedure.